Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia

NCT ID: NCT01854918

Last Updated: 2019-06-11

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

3681 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-04-23

Study Completion Date

2018-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will contribute to the evaluation of long-term safety, tolerability and efficacy of evolocumab (AMG 145) in adults with hyperlipidemia and adults with mixed dyslipidemia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperlipidemia and Mixed Dyslipidemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard of Care

Participants received standard of care (SOC) treatment for the first year of the study (SOC-controlled period). At week 48, participants began treatment with evolocumab at a dose of either 140 mg every 2 weeks (Q2W) or 420 mg every month (QM), based on participant choice, for approximately 2 years during the all-investigational product \[all-IP\] period.

Group Type ACTIVE_COMPARATOR

Evolocumab

Intervention Type BIOLOGICAL

Administered by subcutaneous injection either every 2 weeks or once a month (patient preference) using a prefilled autoinjector pen

Standard of Care

Intervention Type DRUG

Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes

Evolocumab + Standard of Care

Participants received subcutaneous evolocumab plus standard of care during the first year of the study (SOC-controlled period) and for approximately 2 years during the all-IP period. Evolocumab was administered at a dose of 140 mg every 2 weeks (Q2W) or 420 mg every month (QM) based on participant choice.

Group Type EXPERIMENTAL

Evolocumab

Intervention Type BIOLOGICAL

Administered by subcutaneous injection either every 2 weeks or once a month (patient preference) using a prefilled autoinjector pen

Standard of Care

Intervention Type DRUG

Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Evolocumab

Administered by subcutaneous injection either every 2 weeks or once a month (patient preference) using a prefilled autoinjector pen

Intervention Type BIOLOGICAL

Standard of Care

Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

AMG 145 Repatha

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Complete a qualifying evolocumab (AMG 145) parent study (ie, Study 20110114 \[NCT01763827\], 20110115 \[NCT01763866\], 20110116 \[NCT01763905\], 20110117 \[NCT01763918\], 20110109 \[NCT01516879\], 20120122 \[NCT01953328\], 20120332 \[NCT01984424\], 20120348 \[NCT01849497\], or 20120356 \[NCT01879319\]).

Exclusion Criteria

* Experienced a treatment-related serious adverse event that led to study drug discontinuation in the parent study
* Have an unstable medical condition, in the judgment of the investigator
* Known sensitivity to any of the products to be administered during dosing
* Currently enrolled in another investigational device or drug study (excluding evolocumab (AMG 145) parent study), or less than 30 days since ending another investigational device or drug study(s),or receiving other investigational agent(s)
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Amgen

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

MD

Role: STUDY_DIRECTOR

Amgen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Birmingham, Alabama, United States

Site Status

Research Site

Birmingham, Alabama, United States

Site Status

Research Site

Chandler, Arizona, United States

Site Status

Research Site

Phoenix, Arizona, United States

Site Status

Research Site

Tucson, Arizona, United States

Site Status

Research Site

Little Rock, Arkansas, United States

Site Status

Research Site

Beverly Hills, California, United States

Site Status

Research Site

Carmichael, California, United States

Site Status

Research Site

Encinitas, California, United States

Site Status

Research Site

Huntington Beach, California, United States

Site Status

Research Site

Los Angeles, California, United States

Site Status

Research Site

Mission Viejo, California, United States

Site Status

Research Site

Newport Beach, California, United States

Site Status

Research Site

San Diego, California, United States

Site Status

Research Site

Santa Ana, California, United States

Site Status

Research Site

Santa Rosa, California, United States

Site Status

Research Site

Spring Valley, California, United States

Site Status

Research Site

Thousand Oaks, California, United States

Site Status

Research Site

Torrance, California, United States

Site Status

Research Site

Tustin, California, United States

Site Status

Research Site

Ventura, California, United States

Site Status

Research Site

Littleton, Colorado, United States

Site Status

Research Site

Daytona Beach, Florida, United States

Site Status

Research Site

DeLand, Florida, United States

Site Status

Research Site

Jacksonville, Florida, United States

Site Status

Research Site

Melbourne, Florida, United States

Site Status

Research Site

Miami, Florida, United States

Site Status

Research Site

Miami, Florida, United States

Site Status

Research Site

Ponte Vedra, Florida, United States

Site Status

Research Site

Port Charlotte, Florida, United States

Site Status

Research Site

Sanford, Florida, United States

Site Status

Research Site

Atlanta, Georgia, United States

Site Status

Research Site

Atlanta, Georgia, United States

Site Status

Research Site

Atlanta, Georgia, United States

Site Status

Research Site

Gainesville, Georgia, United States

Site Status

Research Site

Savannah, Georgia, United States

Site Status

Research Site

Chicago, Illinois, United States

Site Status

Research Site

Sterling, Illinois, United States

Site Status

Research Site

Indianapolis, Indiana, United States

Site Status

Research Site

Munster, Indiana, United States

Site Status

Research Site

Iowa City, Iowa, United States

Site Status

Research Site

Kansas City, Kansas, United States

Site Status

Research Site

Lexington, Kentucky, United States

Site Status

Research Site

Louisville, Kentucky, United States

Site Status

Research Site

Monroe, Louisiana, United States

Site Status

Research Site

Auburn, Maine, United States

Site Status

Research Site

Bangor, Maine, United States

Site Status

Research Site

Portland, Maine, United States

Site Status

Research Site

Bethesda, Maryland, United States

Site Status

Research Site

Columbia, Maryland, United States

Site Status

Research Site

Towson, Maryland, United States

Site Status

Research Site

Ayer, Massachusetts, United States

Site Status

Research Site

Quincy, Massachusetts, United States

Site Status

Research Site

Ypsilanti, Michigan, United States

Site Status

Research Site

Edina, Minnesota, United States

Site Status

Research Site

Olive Branch, Mississippi, United States

Site Status

Research Site

Tupelo, Mississippi, United States

Site Status

Research Site

St Louis, Missouri, United States

Site Status

Research Site

Henderson, Nevada, United States

Site Status

Research Site

Las Vegas, Nevada, United States

Site Status

Research Site

Endwell, New York, United States

Site Status

Research Site

Manlius, New York, United States

Site Status

Research Site

New Windsor, New York, United States

Site Status

Research Site

New York, New York, United States

Site Status

Research Site

Rochester, New York, United States

Site Status

Research Site

Williamsville, New York, United States

Site Status

Research Site

Raleigh, North Carolina, United States

Site Status

Research Site

Raleigh, North Carolina, United States

Site Status

Research Site

Winston-Salem, North Carolina, United States

Site Status

Research Site

Fargo, North Dakota, United States

Site Status

Research Site

Akron, Ohio, United States

Site Status

Research Site

Cadiz, Ohio, United States

Site Status

Research Site

Canton, Ohio, United States

Site Status

Research Site

Cincinnati, Ohio, United States

Site Status

Research Site

Cincinnati, Ohio, United States

Site Status

Research Site

Cincinnati, Ohio, United States

Site Status

Research Site

Cleveland, Ohio, United States

Site Status

Research Site

Dayton, Ohio, United States

Site Status

Research Site

Mansfield, Ohio, United States

Site Status

Research Site

Marion, Ohio, United States

Site Status

Research Site

Sandusky, Ohio, United States

Site Status

Research Site

Norman, Oklahoma, United States

Site Status

Research Site

Oklahoma City, Oklahoma, United States

Site Status

Research Site

Hillsboro, Oregon, United States

Site Status

Research Site

Duncansville, Pennsylvania, United States

Site Status

Research Site

Lansdale, Pennsylvania, United States

Site Status

Research Site

Pittsburgh, Pennsylvania, United States

Site Status

Research Site

York, Pennsylvania, United States

Site Status

Research Site

Anderson, South Carolina, United States

Site Status

Research Site

Charleston, South Carolina, United States

Site Status

Research Site

Mt. Pleasant, South Carolina, United States

Site Status

Research Site

Rapid City, South Dakota, United States

Site Status

Research Site

Rapid City, South Dakota, United States

Site Status

Research Site

Jackson, Tennessee, United States

Site Status

Research Site

Nashville, Tennessee, United States

Site Status

Research Site

Austin, Texas, United States

Site Status

Research Site

Dallas, Texas, United States

Site Status

Research Site

Dallas, Texas, United States

Site Status

Research Site

Houston, Texas, United States

Site Status

Research Site

Houston, Texas, United States

Site Status

Research Site

San Antonio, Texas, United States

Site Status

Research Site

Norfolk, Virginia, United States

Site Status

Research Site

Richmond, Virginia, United States

Site Status

Research Site

Suffolk, Virginia, United States

Site Status

Research Site

Renton, Washington, United States

Site Status

Research Site

Seattle, Washington, United States

Site Status

Research Site

Tacoma, Washington, United States

Site Status

Research Site

Camperdown, New South Wales, Australia

Site Status

Research Site

Maroubra, New South Wales, Australia

Site Status

Research Site

Sydney, New South Wales, Australia

Site Status

Research Site

Sydney, New South Wales, Australia

Site Status

Research Site

Auchenflower, Queensland, Australia

Site Status

Research Site

Carina Heights, Queensland, Australia

Site Status

Research Site

Sherwood, Queensland, Australia

Site Status

Research Site

Woolloongabba, Queensland, Australia

Site Status

Research Site

Ashford, South Australia, Australia

Site Status

Research Site

Fullarton, South Australia, Australia

Site Status

Research Site

Heidelberg Heights, Victoria, Australia

Site Status

Research Site

Melbourne, Victoria, Australia

Site Status

Research Site

Perth, Western Australia, Australia

Site Status

Research Site

Salzburg, , Austria

Site Status

Research Site

Anthée, , Belgium

Site Status

Research Site

Blankenberge, , Belgium

Site Status

Research Site

Brussels, , Belgium

Site Status

Research Site

Brussels, , Belgium

Site Status

Research Site

Chênée, , Belgium

Site Status

Research Site

Ghent, , Belgium

Site Status

Research Site

Gozée, , Belgium

Site Status

Research Site

Gribomont, , Belgium

Site Status

Research Site

Halen, , Belgium

Site Status

Research Site

Ham, , Belgium

Site Status

Research Site

Hasselt, , Belgium

Site Status

Research Site

La Louvière, , Belgium

Site Status

Research Site

Linkebeek, , Belgium

Site Status

Research Site

Ostend, , Belgium

Site Status

Research Site

Tessenderlo, , Belgium

Site Status

Research Site

Tremelo, , Belgium

Site Status

Research Site

Vilvoorde, , Belgium

Site Status

Research Site

Burnaby, British Columbia, Canada

Site Status

Research Site

Kelowna, British Columbia, Canada

Site Status

Research Site

Surrey, British Columbia, Canada

Site Status

Research Site

Vancouver, British Columbia, Canada

Site Status

Research Site

Bay Roberts, Newfoundland and Labrador, Canada

Site Status

Research Site

Mount Pearl, Newfoundland and Labrador, Canada

Site Status

Research Site

St. John's, Newfoundland and Labrador, Canada

Site Status

Research Site

Cambridge, Ontario, Canada

Site Status

Research Site

Hamilton, Ontario, Canada

Site Status

Research Site

London, Ontario, Canada

Site Status

Research Site

London, Ontario, Canada

Site Status

Research Site

Newmarket, Ontario, Canada

Site Status

Research Site

Oshawa, Ontario, Canada

Site Status

Research Site

Peterborough, Ontario, Canada

Site Status

Research Site

Sarnia, Ontario, Canada

Site Status

Research Site

Toronto, Ontario, Canada

Site Status

Research Site

Toronto, Ontario, Canada

Site Status

Research Site

Toronto, Ontario, Canada

Site Status

Research Site

Woodstock, Ontario, Canada

Site Status

Research Site

Chicoutimi, Quebec, Canada

Site Status

Research Site

Granby, Quebec, Canada

Site Status

Research Site

Greenfield Park, Quebec, Canada

Site Status

Research Site

Lachine, Quebec, Canada

Site Status

Research Site

Montreal, Quebec, Canada

Site Status

Research Site

Montreal, Quebec, Canada

Site Status

Research Site

Montreal, Quebec, Canada

Site Status

Research Site

Pointe-Claire, Quebec, Canada

Site Status

Research Site

Québec, Quebec, Canada

Site Status

Research Site

Brno, , Czechia

Site Status

Research Site

Brno, , Czechia

Site Status

Research Site

Chomutov, , Czechia

Site Status

Research Site

Hradec Králové, , Czechia

Site Status

Research Site

Kladno, , Czechia

Site Status

Research Site

Litoměřice, , Czechia

Site Status

Research Site

Moravské Budějovice, , Czechia

Site Status

Research Site

Olomouc, , Czechia

Site Status

Research Site

Pardubice, , Czechia

Site Status

Research Site

Pilsen, , Czechia

Site Status

Research Site

Prague, , Czechia

Site Status

Research Site

Prague, , Czechia

Site Status

Research Site

Prague, , Czechia

Site Status

Research Site

Prague, , Czechia

Site Status

Research Site

Slaný, , Czechia

Site Status

Research Site

Svitavy, , Czechia

Site Status

Research Site

Aalborg, , Denmark

Site Status

Research Site

Aarhus N, , Denmark

Site Status

Research Site

Ballerup Municipality, , Denmark

Site Status

Research Site

Glostrup Municipality, , Denmark

Site Status

Research Site

Vejle, , Denmark

Site Status

Research Site

Brest, , France

Site Status

Research Site

Bron, , France

Site Status

Research Site

Caen, , France

Site Status

Research Site

Dijon, , France

Site Status

Research Site

Montpellier, , France

Site Status

Research Site

Nantes, , France

Site Status

Research Site

Paris, , France

Site Status

Research Site

Paris, , France

Site Status

Research Site

Vénissieux, , France

Site Status

Research Site

Bad Krozingen, , Germany

Site Status

Research Site

Berlin, , Germany

Site Status

Research Site

Berlin, , Germany

Site Status

Research Site

Cologne, , Germany

Site Status

Research Site

Dresden, , Germany

Site Status

Research Site

Hellersdorf, , Germany

Site Status

Research Site

Heppenheim an der Bergstrasse, , Germany

Site Status

Research Site

Homburg, , Germany

Site Status

Research Site

Leipzig, , Germany

Site Status

Research Site

Magdeburg, , Germany

Site Status

Research Site

Messkirch, , Germany

Site Status

Research Site

München, , Germany

Site Status

Research Site

Witten, , Germany

Site Status

Research Site

Hong Kong, , Hong Kong

Site Status

Research Site

New Territories, , Hong Kong

Site Status

Research Site

Baja, , Hungary

Site Status

Research Site

Berettyóújfalu, , Hungary

Site Status

Research Site

Budapest, , Hungary

Site Status

Research Site

Eger, , Hungary

Site Status

Research Site

Gyöngyös, , Hungary

Site Status

Research Site

Hódmezővásárhely, , Hungary

Site Status

Research Site

Jászberény, , Hungary

Site Status

Research Site

Komárom, , Hungary

Site Status

Research Site

Mosonmagyaróvár, , Hungary

Site Status

Research Site

Pécs, , Hungary

Site Status

Research Site

Szeged, , Hungary

Site Status

Research Site

Bologna, , Italy

Site Status

Research Site

Cagliari, , Italy

Site Status

Research Site

Chieti, , Italy

Site Status

Research Site

Cinisello Balsamo (MI), , Italy

Site Status

Research Site

Ferrara, , Italy

Site Status

Research Site

Milan, , Italy

Site Status

Research Site

Napoli, , Italy

Site Status

Research Site

Padua, , Italy

Site Status

Research Site

Perugia, , Italy

Site Status

Research Site

Pisa, , Italy

Site Status

Research Site

Pisa, , Italy

Site Status

Research Site

Trieste, , Italy

Site Status

Research Site

Noda, Chiba, Japan

Site Status

Research Site

Fukuoka, Fukuoka, Japan

Site Status

Research Site

Fukuoka, Fukuoka, Japan

Site Status

Research Site

Fukuoka, Fukuoka, Japan

Site Status

Research Site

Kitakyusyu-shi, Fukuoka, Japan

Site Status

Research Site

Koriyama-shi, Fukushima, Japan

Site Status

Research Site

Koriyama-shi, Fukushima, Japan

Site Status

Research Site

Koriyama-shi, Fukushima, Japan

Site Status

Research Site

Koriyama-shi, Fukushima, Japan

Site Status

Research Site

Koriyama-shi, Fukushima, Japan

Site Status

Research Site

Maebashi, Gunma, Japan

Site Status

Research Site

Takasaki-shi, Gunma, Japan

Site Status

Research Site

Sapporo, Hokkaido, Japan

Site Status

Research Site

Sapporo, Hokkaido, Japan

Site Status

Research Site

Sapporo, Hokkaido, Japan

Site Status

Research Site

Tsuchiura-shi, Ibaraki, Japan

Site Status

Research Site

Morioka, Iwate, Japan

Site Status

Research Site

Takamatsu, Kagawa-ken, Japan

Site Status

Research Site

Takamatsu, Kagawa-ken, Japan

Site Status

Research Site

Yokohama, Kanagawa, Japan

Site Status

Research Site

Kyoto, Kyoto, Japan

Site Status

Research Site

Sendai, Miyagi, Japan

Site Status

Research Site

Sendai, Miyagi, Japan

Site Status

Research Site

Sendai, Miyagi, Japan

Site Status

Research Site

Tomigusuku-shi, Okinawa, Japan

Site Status

Research Site

Ibaraki-shi, Osaka, Japan

Site Status

Research Site

Toyonaka-shi, Osaka, Japan

Site Status

Research Site

Koshigaya-shi, Saitama, Japan

Site Status

Research Site

Niiza-shi, Saitama, Japan

Site Status

Research Site

Arakawa-ku, Tokyo, Japan

Site Status

Research Site

Chiyoda-ku, Tokyo, Japan

Site Status

Research Site

Chofu-shi, Tokyo, Japan

Site Status

Research Site

Edogawa-ku, Tokyo, Japan

Site Status

Research Site

Hachioji-shi, Tokyo, Japan

Site Status

Research Site

Katsushika-ku, Tokyo, Japan

Site Status

Research Site

Koto-ku, Tokyo, Japan

Site Status

Research Site

Minato-ku, Tokyo, Japan

Site Status

Research Site

Minato-ku, Tokyo, Japan

Site Status

Research Site

Ōta-ku, Tokyo, Japan

Site Status

Research Site

Setagaya-ku, Tokyo, Japan

Site Status

Research Site

Shibuya-ku, Tokyo, Japan

Site Status

Research Site

Shinagawa-ku, Tokyo, Japan

Site Status

Research Site

Shinagawa-ku, Tokyo, Japan

Site Status

Research Site

Shinagawa-ku, Tokyo, Japan

Site Status

Research Site

Shinagawa-ku, Tokyo, Japan

Site Status

Research Site

Toshima-ku, Tokyo, Japan

Site Status

Research Site

Amsterdam, , Netherlands

Site Status

Research Site

Den Helder, , Netherlands

Site Status

Research Site

Groningen, , Netherlands

Site Status

Research Site

Groningen, , Netherlands

Site Status

Research Site

Hoogeveen, , Netherlands

Site Status

Research Site

Hoorn, , Netherlands

Site Status

Research Site

Nijmegen, , Netherlands

Site Status

Research Site

Rotterdam, , Netherlands

Site Status

Research Site

Tilburg, , Netherlands

Site Status

Research Site

Utrecht, , Netherlands

Site Status

Research Site

Waalwijk, , Netherlands

Site Status

Research Site

Zwijndrecht, , Netherlands

Site Status

Research Site

Christchurch, , New Zealand

Site Status

Research Site

Ålesund, , Norway

Site Status

Research Site

Oslo, , Norway

Site Status

Research Site

Lodz, , Poland

Site Status

Research Site

Barnaul, , Russia

Site Status

Research Site

Kemerovo, , Russia

Site Status

Research Site

Moscow, , Russia

Site Status

Research Site

Novosibirsk, , Russia

Site Status

Research Site

Saint Petersburg, , Russia

Site Status

Research Site

Saratov, , Russia

Site Status

Research Site

Centurion, Gauteng, South Africa

Site Status

Research Site

Johannesburg, Gauteng, South Africa

Site Status

Research Site

Midrand, Gauteng, South Africa

Site Status

Research Site

Sunninghill, Gauteng, South Africa

Site Status

Research Site

eManzimtoti, KwaZulu-Natal, South Africa

Site Status

Research Site

Observatory, Western Cape, South Africa

Site Status

Research Site

Paarl, Western Cape, South Africa

Site Status

Research Site

Parow, Western Cape, South Africa

Site Status

Research Site

Somerset West, Western Cape, South Africa

Site Status

Research Site

Bloemfontein, , South Africa

Site Status

Research Site

Seoul, , South Korea

Site Status

Research Site

Seoul, , South Korea

Site Status

Research Site

Córdoba, Andalusia, Spain

Site Status

Research Site

Zaragoza, Aragon, Spain

Site Status

Research Site

L'Hospitalet de Llobregat, Catalonia, Spain

Site Status

Research Site

Reus, Catalonia, Spain

Site Status

Research Site

Madrid, , Spain

Site Status

Research Site

Madrid, , Spain

Site Status

Research Site

Madrid, , Spain

Site Status

Research Site

Gothenburg, , Sweden

Site Status

Research Site

Lund, , Sweden

Site Status

Research Site

Örebro, , Sweden

Site Status

Research Site

Stockholm, , Sweden

Site Status

Research Site

Stockholm, , Sweden

Site Status

Research Site

Stockholm, , Sweden

Site Status

Research Site

Uddevalla, , Sweden

Site Status

Research Site

Bellinzona, , Switzerland

Site Status

Research Site

Geneva, , Switzerland

Site Status

Research Site

Lausanne, , Switzerland

Site Status

Research Site

Lugano, , Switzerland

Site Status

Research Site

Muensterlingen, , Switzerland

Site Status

Research Site

Reinach, , Switzerland

Site Status

Research Site

Sankt Gallen, , Switzerland

Site Status

Research Site

Zurich, , Switzerland

Site Status

Research Site

Zurich, , Switzerland

Site Status

Research Site

Kaohsiung City, , Taiwan

Site Status

Research Site

Taipei, , Taiwan

Site Status

Research Site

Birmingham, , United Kingdom

Site Status

Research Site

Birmingham, , United Kingdom

Site Status

Research Site

Blackpool, , United Kingdom

Site Status

Research Site

Cardiff, , United Kingdom

Site Status

Research Site

Chesterfield, , United Kingdom

Site Status

Research Site

Chorley, , United Kingdom

Site Status

Research Site

Coventry, , United Kingdom

Site Status

Research Site

Doncaster, , United Kingdom

Site Status

Research Site

Glasgow, , United Kingdom

Site Status

Research Site

Glasgow, , United Kingdom

Site Status

Research Site

Glasgow, , United Kingdom

Site Status

Research Site

Liverpool, , United Kingdom

Site Status

Research Site

Liverpool, , United Kingdom

Site Status

Research Site

London, , United Kingdom

Site Status

Research Site

London, , United Kingdom

Site Status

Research Site

London, , United Kingdom

Site Status

Research Site

Manchester, , United Kingdom

Site Status

Research Site

Manchester, , United Kingdom

Site Status

Research Site

Newcastle upon Tyne, , United Kingdom

Site Status

Research Site

Reading, , United Kingdom

Site Status

Research Site

Telford, , United Kingdom

Site Status

Research Site

Wakefield, , United Kingdom

Site Status

Research Site

West Bromwich, , United Kingdom

Site Status

Research Site

Whitby, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Austria Belgium Canada Czechia Denmark France Germany Hong Kong Hungary Italy Japan Netherlands New Zealand Norway Poland Russia South Africa South Korea Spain Sweden Switzerland Taiwan United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Kasichayanula S, Grover A, Emery MG, Gibbs MA, Somaratne R, Wasserman SM, Gibbs JP. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. Clin Pharmacokinet. 2018 Jul;57(7):769-779. doi: 10.1007/s40262-017-0620-7.

Reference Type BACKGROUND
PMID: 29353350 (View on PubMed)

Sattar N, Toth PP, Blom DJ, Koren MJ, Soran H, Uhart M, Elliott M, Cyrille M, Somaratne R, Preiss D. Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus. Am J Cardiol. 2017 Nov 1;120(9):1521-1527. doi: 10.1016/j.amjcard.2017.07.047. Epub 2017 Jul 31.

Reference Type RESULT
PMID: 28844508 (View on PubMed)

Hovingh GK, Raal FJ, Dent R, Stefanutti C, Descamps O, Masana L, Lira A, Bridges I, Coll B, Sullivan D. Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia. J Clin Lipidol. 2017 Nov-Dec;11(6):1448-1457. doi: 10.1016/j.jacl.2017.09.003. Epub 2017 Sep 22.

Reference Type RESULT
PMID: 29066265 (View on PubMed)

Schmidt AF, Carter JL, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020 Oct 20;10(10):CD011748. doi: 10.1002/14651858.CD011748.pub3.

Reference Type DERIVED
PMID: 33078867 (View on PubMed)

Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16;372(16):1500-9. doi: 10.1056/NEJMoa1500858. Epub 2015 Mar 15.

Reference Type DERIVED
PMID: 25773607 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

http://www.amgentrials.com

AmgenTrials clinical trials website

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2012-004357-83

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

20120138

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.